The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

Biologics have transformed the treatment of immune-mediated inflammatory diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars—biologic medicines with no clinically meaningful differences in safety or efficacy from licensed originators—can stimulate market comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, HoUng, Alten, Rieke, Avedano, Luisa, Dignass, Axel, Gomollón, Fernando, Greveson, Kay, Halfvarson, Jonas, Irving, Peter M., Jahnsen, Jørgen, Lakatos, Péter L., Lee, JongHyuk, Makri, Souzi, Parker, Ben, Peyrin-Biroulet, Laurent, Schreiber, Stefan, Simoens, Steven, Westhovens, Rene, Danese, Silvio, Jeong, Ji Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Leading Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007415/
https://www.ncbi.nlm.nih.gov/pubmed/32002851
http://dx.doi.org/10.1007/s40265-020-01256-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007415/
https://www.ncbi.nlm.nih.gov/pubmed/32002851
http://dx.doi.org/10.1007/s40265-020-01256-5

Ejemplares similares